What do we know and what can we really do for families with familial hypercholesterolemia: case report
Familial hypercholesterolemia is a disorder which does not “hurt”. The brief case report presents the story of a patient in which neither he or his family were compliant...
Authors: Katarína Rašlová, Miloslava Hučková
Opinion of the Committee of the Czech Society for Atherosclerosis on the ESC/ EAS Recommendations for Dyslipidemia Diagnostics and Treatment 2016
The Committee of the Czech Society for Atherosclerosis (CSAT) has drawn up an opinion on the ESC/EAS new recommendations for the management of dyslipidemias published in 2016...
Authors: Michal Vrablík, Jan Piťha, Vladimír Bláha, Renata Cífková, Tomáš Freiberger, Pavel Kraml, Hana Rosolová, Vladimír Soška, Tomáš Štulc, Zuzana Urbanová, Helena Vaverková
Secondary dyslipidemia (DLP) arises as a result of other diseases or various exogenous influences. However, genetic predisposition, as it is known in the case of primary DLP...
Authors: Martin Šatný, Michal Vrablík
Intensive treatment of dyslipidemia in regional outpatient cardiology office
We presented briefly initial experiences of outpatient cardiologist in the first ever MedPed center in the Orava region. Reduction of low-density lipoprotein cholesterol (LDL...
The role of functional food and nutraceuticals in therapy of hypercholesterolemia
Dyslipidemia, arterial hypertension, smoking and type 2 diabetes mellitus are the most important risk factors for cardiovascular diseases (CVD). The first step in treatment of...
Myths on diet and prevention of atherosclerosis
Cardiovascular disease is globally the number one cause of premature death and disability. Physical activities and good nutrition play a crucial role in maintaining health and...
What is the role of nutriceuticals in dyslipidemia management? Armolipid Plus
Low density lipoprotein-cholesterol (LDL-C) reduction is the basic approach in the treatment and prevention of cardiovascular disease on the atherosclerosis background. Except...
The study ODYSSEY CHOICE I with alirocumab: more data on PCSK9 inhibition
The search for an optimum method of inhibiting proprotein convertase subtilisin kexin (PCSK9) goes on and the clinical researches into monoclonal antibodies to PCSK9 (PCSK9...
Authors: Michal Vrablík, Eva Tůmová
Effect of statins and ezetimibe on the progression of atherosclerosis
Recent years have brought a significant amount of new results in the field of atherosclerosis. It is well recognized that low-density lipoprotein cholesterol (LDL-C) lowering...
Results of FOURIER study – beginning of the new era in cardiovascular disease prevention?
Increased levels of LDL-cholesterol (LDL-C) represent serious risk factor in the pathogenesis of atherosclerosis and its complications. There were no new approaches how to reach...
SubscriptionSubscribe the Journal
The subscription grants you full access to all the articles.
Issue No.: 3 / 2017
- What is the role of nutriceuticals in dyslipidemia management? Armolipid Plus | views: 147
- The common position of the Czech professional associations on the consensus of the European Atherosclerosis Society and the European Federation of Clinical Chemistry and Laboratory Medicine regarding investigation on blood lipids and interpretation of their levels | views: 130
- The review of drug interactions and risks of statin therapy | views: 124
- Effect of statins and ezetimibe on the progression of atherosclerosis | views: 87
- The study ODYSSEY CHOICE I with alirocumab: more data on PCSK9 inhibition | views: 75